GLP-1: A Prospective Guardian for Comprehensive Myocardial Perfusion

IF 6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes/Metabolism Research and Reviews Pub Date : 2024-11-09 DOI:10.1002/dmrr.70004

Zhi Li, Yao Yu, Jie Li, Xiaoqiong Jiang, Jie Chen, Ning Ye, Boquan Wu, Yingxian Sun, Guozhe Sun

{"title":"GLP-1: A Prospective Guardian for Comprehensive Myocardial Perfusion","authors":"Zhi Li, Yao Yu, Jie Li, Xiaoqiong Jiang, Jie Chen, Ning Ye, Boquan Wu, Yingxian Sun, Guozhe Sun","doi":"10.1002/dmrr.70004","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To investigate the role of glucagon-like peptide 1 (GLP-1) in myocardial perfusion, focusing on its effects on coronary microcirculation and cardiovascular outcomes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Review of foundational research and large-scale clinical trials, including Cardiovascular Outcome Trials (CVOTs), examining the cardiovascular effects of GLP-1. Systematic analysis of trial data to assess the impact of GLP-1 therapy on myocardial infarction, composite cardiovascular events, and stroke incidence.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>GLP-1 therapy was found to significantly reduce myocardial infarction and composite cardiovascular events. Additionally, GLP-1 receptor agonists were observed to reduce stroke incidence, suggesting systemic effects on panvascular diseases. While direct protective effects on coronary microvasculature have been less studied, growing evidence supports GLP-1's role in comprehensive myocardial perfusion.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>GLP-1 is a promising therapeutic agent for improving myocardial perfusion and reducing cardiovascular events. Its protection is likely associated with comprehensive improvements in myocardial perfusion, including effects on coronary microcirculation. Further research is needed to fully elucidate its mechanisms of action and potential clinical applications.</p>\n </section>\n </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"40 8","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70004","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To investigate the role of glucagon-like peptide 1 (GLP-1) in myocardial perfusion, focusing on its effects on coronary microcirculation and cardiovascular outcomes.

Methods

Review of foundational research and large-scale clinical trials, including Cardiovascular Outcome Trials (CVOTs), examining the cardiovascular effects of GLP-1. Systematic analysis of trial data to assess the impact of GLP-1 therapy on myocardial infarction, composite cardiovascular events, and stroke incidence.

Results

GLP-1 therapy was found to significantly reduce myocardial infarction and composite cardiovascular events. Additionally, GLP-1 receptor agonists were observed to reduce stroke incidence, suggesting systemic effects on panvascular diseases. While direct protective effects on coronary microvasculature have been less studied, growing evidence supports GLP-1's role in comprehensive myocardial perfusion.

Conclusion

GLP-1 is a promising therapeutic agent for improving myocardial perfusion and reducing cardiovascular events. Its protection is likely associated with comprehensive improvements in myocardial perfusion, including effects on coronary microcirculation. Further research is needed to fully elucidate its mechanisms of action and potential clinical applications.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

GLP-1：全面心肌灌注的前瞻性监护仪。

目的研究胰高血糖素样肽 1（GLP-1）在心肌灌注中的作用，重点研究其对冠状动脉微循环和心血管预后的影响：方法：回顾基础研究和大规模临床试验，包括心血管预后试验（CVOTs），研究 GLP-1 对心血管的影响。对试验数据进行系统分析，评估 GLP-1 疗法对心肌梗死、复合心血管事件和中风发病率的影响：结果：GLP-1疗法可显著降低心肌梗死和复合心血管事件的发生率。此外，还观察到 GLP-1 受体激动剂可降低中风发病率，这表明它对泛血管疾病具有系统性影响。虽然对冠状动脉微血管的直接保护作用研究较少，但越来越多的证据支持 GLP-1 在全面心肌灌注中的作用：结论：GLP-1 是改善心肌灌注和减少心血管事件的一种有前途的治疗药物。其保护作用可能与心肌灌注的全面改善有关，包括对冠状动脉微循环的影响。要全面阐明其作用机制和潜在的临床应用，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢

CiteScore

17.20

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.